1
2
3
We don't have analytics for this instrument yet. You can contribute!
Please log in and be the first author to write an article about this instrument!
Madrigal Pharmaceuticals, Inc. (NASDAQ)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Trading schedule (UTC)
Open Now
Closed Now
Closes on
Opening on
at
-
This shows the opening hours in your local time zone
(UTC)
Ticker | MDGL |
Contract value | 100 shares |
Maximum leverage | 1:5 |
Swaps history
Date | Short Swap (%) | Long Swap (%) | No data |
---|
Minimum transaction volume | 0.01 lot |
Maximum transaction volume | 100 lots |
Hedging margin | 50% |